Because Akt activation is a direct consequence of E-cadherin loss, functional inactivation of E-cadherin and the AJ, rather than the presence of oncogenic mutations in this PI3K/Akt pathway, should be used as inclusion criteria for clinical PI3K/Akt intervention trials in this breast cancer subtype. This evidence concerns the gene PIK3CA and breast carcinoma.